KR20230090092A - Antidiabetic red bean extract composition for lowering blood glucose level and increasing diet effect - Google Patents

Abstract

The present invention relates to a food composition using red bean YV1-138 or allied species thereof, which is effective in preventing or alleviating diabetes or obesity, and can be widely used in the use of red bean processed foods with anti-obesity and anti-diabetic effects. The food composition includes red bean variety YV1-138 or a secondary extract of allied species thereof.

Description

Antidiabetic red bean extract composition for lowering blood glucose level and increasing diet effect}

The present invention is effective for preventing or improving diabetes or obesity of adzuki bean YV1-138 or its relatives, and relates to a food composition using the same.

BACKGROUND OF THE INVENTION Due to changes in diet and lifestyle following rapid economic development in modern society, average life expectancy has been extended, while chronic degenerative diseases such as diabetes and obesity are gradually increasing.

Causes of obesity include genetic factors, environmental factors, abnormalities in energy metabolism, etc., and types of obesity can be classified into simple obesity and symptomatic obesity according to the cause. Simple obesity is caused by overeating and lack of exercise, and symptomatic obesity is caused by endocrine, hypothalamic, genetic, frontal and metabolic factors. Obesity may not be a problem in itself, but secondary complications caused by social disorders and excessive fat caused by it are serious. For example, obesity can significantly increase the incidence of diabetes and the like.

In Korea, it was reported that 4 million people, or 8% of the population, had diabetes in 2004. In particular, diet is very important in the management of patients with type 2 diabetes, and is fundamentally to control hyperglycemia. If postprandial hyperglycemia is not controlled, it can promote visual impairment, neurological impairment, renal dysfunction, and cardiac dysfunction due to retinopathy, a chronic diabetic complication. Therefore, people with diabetes must prevent a rapid rise in blood sugar by gradually absorbing carbohydrates from food they eat.

Alpha-glucosidase inhibitors (α-glucosidase inhibitors) are drugs that have been developed and used to solve these problems. Alpha-glucosidase is an enzyme that hydrolyzes oligosaccharides digested in the small intestine into monosaccharides. Therefore, the development of this enzyme inhibitor will be of great help in the treatment of diabetes and obesity by mitigating the level of postprandial blood sugar rise by delaying carbohydrate absorption. Therefore, many studies have been conducted on the inhibition of alpha-glucosidase, which is essential for carbohydrate metabolism, for use in lowering blood sugar levels. In particular, in 1977, Bayer, Germany, developed miglitol, a derivative of acaebos (Schmidt, D.D., etc., Naturwis senschaften, 1977, 64, 535) and deoxynojirimycin, which was used to treat diabetes. And it has been developed and marketed as a treatment for obesity.

To date, many types of diabetes and obesity treatments have been developed and are under development, but satisfactory drugs have not been developed. Currently, oral hypoglycemic drugs such as sulfonyl urea and meglitinide can cause hypoglycemia, colds, and headaches when taken with other drugs, and biguanide can cause gastrointestinal disorders. And it has a problem of causing renal toxicity. Therefore, efforts are being made to develop alpha-glucosidase inhibitors that have relatively few side effects and can control blood glucose control as a therapeutic agent for diabetes.

On the other hand, red bean (Vigna angularis) has been known to be effective for kidney disease, feces, tumors, and childbirth diseases since ancient times, and is also used as a folk remedy. Red bean saponins (DDMPsaponins) show antioxidant effects and free radical scavenging activity, and hot water extracts are known to stimulate tyrosinase activity and inhibit whitening of hair. Korean Patent Publication No. 10-2010-0078830 discloses that among the related species of red beans, Vigna nakashimae has higher alpha-glucosidase inhibitory activity than other related species of red beans. However, research on changes in the α-glucosidase inhibitory activity and processing methods for increasing it during processing of red beans has not been reported to date, making it difficult to utilize the antidiabetic and antiobesity using the red beans.

In addition, in order to use red beans as a processed food, it is necessary to go through a treatment process such as heating. In order to use them in the form of health food, it is easy to develop various products in the form of extracts using a solvent, but red beans YV1-138 requires direct processing for processing. When heat treatment is performed, the antidiabetic activity rapidly decreases, and crude extracts such as ethanol tend to be unstable to heat.

Under this background, the present inventors, using YV1-138 or its related red beans with high alpha-glucosidase inhibitory activity, developed a red bean processing method to increase antidiabetic and antiobesity activity by using an organic solvent during intensive research efforts. The present invention was completed by confirming that the extract was separated and concentrated using secondary extraction, and that the concentrated extract had stability and significantly increased antidiabetic and antiobesity activity.

One object of the present invention is to provide a food composition for preventing or improving diabetes or obesity, comprising a secondary extract of adzuki bean variety YV1-138 or a related species thereof.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes or obesity, comprising an extract of adzuki bean variety YV1-138 and related strains.

Specifically, this is as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention belong to the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.

In addition, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Also, such equivalents are intended to be included in this invention.

As one aspect for achieving the above object, a food composition for preventing or improving diabetes or obesity, comprising a secondary extract of adzuki bean variety YV1-138 or a related species thereof, is provided.

The term "red bean" of the present invention is an annual plant of the leguminous dicotyledonous plant, and is divided into common red beans with straight stems and tendrilous red beans, depending on ecological characteristics. It is known that red bean, black red bean, blue red bean, and stained red bean are classified according to the type of red bean.

The term in the present invention, “YV1-138 (Vigna angularis 'YV1-138')” is a red bean variety, with 'Gyeongwon Red Bean (No. 988)' having strong uniformity resistance as the parent and 'Jomdol Red Bean (IT178464)' as the counterpart It is a breed that has been bred by artificial breeding.

The YV1-138 has been deposited with the National Academy of Agricultural Sciences, a depository under the Budapest Treaty, on October 30, 2018, and has been deposited under the accession number KACC 98056P.

The term of the present invention, "closed species" means a kind with a deep relationship in the classification of organisms, and may mean both progeny lines having the same parent and parent as YV1-138. In the present invention, it may be a variety obtained by artificially crossing Gyeongwon red bean as a parent and IT178464, a small stone red bean, as a female, but is not limited thereto.

The term “extract” of the present invention refers to a liquid component obtained by immersing a target material in various solvents and then extracting at room temperature or at elevated temperature for a certain period of time, and a solid component obtained by removing the solvent from the liquid component. do. The extraction may be performed one or more times, but is not limited thereto. In addition, it can be comprehensively interpreted as including all of the filtrates, dilutions, concentrates thereof, adjusted products, and purified products of the results.

Accordingly, the secondary extract of adzuki bean YV1-138 or its related species provided in the present invention is an extract obtained by extracting adzuki bean YV1-138 or its related species, a purified product obtained by enzymatic digestion of the extract, or a mixture thereof, It can be interpreted as including the extract itself and the extract of all formulations that can be formed using the extract itself and the extract.

The method for extracting red bean YV1-138 or its related species of the present invention is not particularly limited, and can be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.

In the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water, alcohol, or a mixed solvent thereof, which may be used alone or in combination of two or more, and in the case of using alcohol as a solvent, specifically having 1 to 1 carbon atoms. 4 alcohols can be used. Specifically, distilled water may be used, but is not limited thereto.

In one embodiment of the present invention, primary extraction was performed with 15 to 95%, specifically 40 to 90%, and more specifically 60 to 85% ethanol, and secondary extraction was performed using an organic solvent to obtain 15 to 95 By confirming that the alpha-glucosidase inhibitory activity increased 2 to 5 times, specifically 2.5 to 4.5 times compared to the % ethanol primary extraction, it was confirmed that it was excellent in antidiabetic and antiobesity (obesity suppression) activities (Tables 1 to 3). 2).

In addition, by performing the secondary extraction using an organic solvent, it was confirmed that the thermal stability was excellent compared to the primary extraction with 15 to 95% ethanol (Table 3).

As the organic solvent used for the secondary extraction, petroleum ethanol, 2-propanol, ether, cyclohexane, benzene, chloroform, ether, ethyl acetate, acetone, isopropyl alcohol, methylene chloride, xylene, glycerin, ethyl acetate, sulfide carbon, butanol and methanol; and the like, but are not limited thereto. For example, 15 to 95% ethanol, specifically 40 to 80% ethanol, more specifically 45 to 60% ethanol or 2-propanol may be used, but is not limited thereto.

As used herein, the term "diabetes" refers to a disease that occurs when the secretion of insulin is insufficient or the action and function of insulin are not sufficiently achieved. Specifically, excessive decomposition of glycogen, protein, and fat causes an abnormal increase in glucose concentration in the liver or blood, resulting in diabetes and ketonuria, abnormal water and electrolyte metabolism, circulatory disorders with blood concentration due to loss of electrolyte chambers, It can lead to morbid conditions such as kidney failure. Insulin is secreted from β-cells of pancreatic islets in the pancreas when blood glucose concentration increases, and secretion is suppressed when blood glucose concentration decreases, thereby controlling the appropriate activity of an energy source. Diagnosis of diabetes is generally possible through measurement of blood glucose concentration. In humans, diabetes is generally diagnosed when blood glucose is usually 200 mg/dl or more and 140 mg/dl or more when fasting. Therefore, it can be usefully used for treatment or prevention of diabetes by restoring damaged pancreatic β-cells or increasing glucose uptake in pancreatic islet cells. In the present invention, the diabetes may be type 1 diabetes or type 2 diabetes, and the terms “diabetes” or “diabetes” may be used interchangeably.

As used herein, the term "obesity" refers to a state in which fat is excessive in the body, and specifically, the body mass index (body mass index: weight (kg) divided by the square of height (m)) is A score above 25 is defined as obese. Obesity can be caused by very complex causes such as genetic and environmental factors, but as a result, over a long period of time, excessive intake of nutrients compared to energy consumption results in fat accumulation due to energy imbalance. If you become obese, the possibility of developing diabetes and hyperlipidemia increases, and the risk of developing sexual dysfunction, arthritis, and cardiovascular disease may increase.

As used herein, the term "anti-diabetic" refers to a substance effective in preventing or treating diabetes.

As used herein, the term "anti-obesity" refers to a substance effective in preventing or treating obesity.

The term "prevention" refers to any action that suppresses or delays the onset of a disease.

The term "improvement" refers to suppressing or inhibiting the symptoms of a disease, or alleviating the symptoms of a disease that has already developed.

The term "alpha-glucosidase" in the present invention refers to the digestion of carbohydrates in the small intestine by breaking down unabsorbed polysaccharides and disaccharides into monosaccharides in the small intestine.

It is a degrading enzyme that promotes

Specifically, in the present invention, the secondary extract of adzuki bean YV1-138 or its related species may increase or maintain alpha-glucosidase inhibitory activity.

In one embodiment of the present invention, it was confirmed that the diet (feed) containing the secondary extract of adzuki bean YV1-138 or its related species was fed, and the effect of improving diabetes and obesity through blood sugar change was excellent (FIGS. 2 to 3).

The term "food" of the present invention refers to meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, There are vitamin complexes, functional foods, and health foods, which include all foods in a conventional sense, and are not limited thereto as long as the adzuki bean YV1-138 or its related species can be included.

In the case of the processed food, it is cold chained to maintain a state suitable for quality maintenance throughout the entire distribution process until reaching the consumer, and the low-temperature distribution period of the processed product with increased alpha-glucosidase inhibitory activity. For verification, the need to inhibit microbial development is required.

The “food composition” of the present invention may further include a physiologically acceptable carrier. The type of carrier is not particularly limited and is commonly used in the art.

Any carrier can be used as long as it is used.

In addition, the food composition may include additional ingredients that are commonly used in food compositions and can improve smell, taste, and vision. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chrome (Cr) may be included.

there is. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included.

In addition, the food composition may include preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butyl hydroxy Loxytoluene (BHT), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite, etc.), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin) , sodium, etc.), flavoring (vanillin, lactones, etc.), expanding agent (alum, D-potassium hydrogen stannate, etc.), strengthening agent, emulsifier, thickener (thickener), coating agent, gum base agent, foam inhibitor, solvent, improver, etc. food May contain food additives. The additive may be selected according to the type of food and used in an appropriate amount.

Another aspect of the present invention provides a pharmaceutical composition for preventing or treating diabetes or obesity, comprising a secondary extract of adzuki bean variety YV1-138 or a related species thereof.

The term "treatment" means that the symptoms of a disease-affected subject are improved or beneficially changed.

means all actions.

The “red bean”, “YV1-138”, “extract” and “prevention” are as described above.

The secondary extract of red bean YV1-138 or its related species of the present invention has increased alpha-glucosidase inhibitory activity and is effective in preventing or improving obesity and diabetes, so it is widely used in red bean processed foods having anti-obesity and anti-diabetic effects. will be able to utilize

Figure 1 shows the results of UPLC analysis of red beans according to the extraction method of red beans YV1-138 or its relatives, (A) 205 nm, 80% ethanol extract, (B) 260 nm, 80% ethanol extract, (C ) is a graph of 205 nm, 2-propanol extract, (D) is 260 nm, 2-propanol extract.
Figure 2A is a graph showing the effect of improving body weight when ingesting a secondary extract of adzuki bean YV1-138 or its close relative in an animal experimental model.
Figure 2B is a morphological photograph of a mouse showing an effect of improving body weight when ingesting a secondary extract of adzuki bean YV1-138 or its close relative in an animal experimental model.
3 is a graph showing changes in fasting blood glucose in an animal experimental model.

Hereinafter, the present invention will be described in more detail through experimental examples and examples. However, the following experimental examples and examples are merely illustrative of the contents of the present invention, and the scope of the present invention is not limited to the following experimental examples and examples. The experimental examples and examples of the present invention are provided to more completely explain the present invention to those skilled in the art.

Experimental Example 1: Preparation of adzuki bean YV1-138 or its close relatives.

Red bean YV1-138 or its related species deposited under accession number KACC 98056P used red bean and Gyeongwon red bean produced in 2020 in the packaging of the Southern Crop Department of the National Institute of Crop Science.

Experimental Example 2. Preparation of red bean extract

After pulverizing the anti-diabetic red bean seeds with a grinder, 20 L of 80% ethane per 1 kg of sample was added, followed by stirring and extraction at 280 rpm for 48 hours at room temperature. The extracted sample was centrifuged at 3,000 rpm to take the supernatant, concentrated under reduced pressure at 45 ° C or less, and then lyophilized. 20 ml of 25% ethanol, 50% ethanol, and 2-propanol (isopropyl alcohol, for food) having different polarities were added to each 1 g of the same-dried sample, followed by stirring and extraction at 280 rpm for 24 hours at room temperature.

The secondary extract of adzuki bean YV1-138 or its related species was then used for the following alpha-glucosidase activity assay and fasting blood glucose measurement.

Experimental Example 3. Analysis of alpha-glucosidase inhibitory activity

Alpha-glucosidase inhibitory activity of the secondary extract of adzuki bean YV1-138 or its related species in Experimental Example 2 was measured.

Specifically, the enzyme alpha-glucosidase, the substrate para-nitrophenyl-alpha-D-glucopyranoside, and the oral hypoglycemic agent acarbose were produced by Sigma. It was purchased and used, and 0.1 M phosphate buffer (pH 7.0) was prepared and used directly.

10 μl of the extract extracted from the sample to which the above extraction method was applied was added to 10 μl of 0.275 units/mL alpha-glucosidase in 103 μl of 0.1 M phosphate buffer, and then 2.5 mM para-nitrophenyl-alpha-D-glucopy as a substrate After adding 20 μl of lanoside and reacting in an incubator at 37° C. for 20 minutes, 50 μl of 200 mM sodium carbonate (Na ₂ CO ₃ ) was added to stop the reaction, and absorbance was measured at 405 nm. IC ₅₀ was calculated by linear regression analysis, and acarbose was used as a positive control. All assays were performed in triplicate.

Experimental Example 4. Preparation of diabetic or obese animal models

3-week-old male C57BL/6 mice were purchased from Coretech Co., Ltd. (Pyeongtaek, Korea) and bred in the animal laboratory of Gyeongsang National University, where they were stabilized for one week.

Groups (10 animals each) fed with a normal diet (feed) or 45% Kcal fat (US Research Diet) for 8 weeks from 4 weeks of age were prepared by dividing into 5 groups as follows.

- ND (Normal diet, normal group) is a group that consumed a normal diet,

- HFD (High-fat diet, high-fat group) is the group that consumed 45% kcal high-fat diet,

- HFD V50 was a group that consumed feed mixed with 50mg/kg of red bean extract in high-fat feed,

- HFD V200 was a group that consumed feed mixed with 200mg/kg of red bean extract in high-fat feed,

- ND V200 is a group that consumed feed mixed with 200mg/kg of red bean extract in general feed

Experimental Example 5. Fasting blood glucose measurement method

To measure fasting blood sugar, fasting was performed for 12 hours, weight was measured at 9 am the next day, and blood was collected from the tail of the mouse using an Accu-Chek glucometer (Roche Diagnostics GmbH, Mannheim, Germany). blood sugar was measured.

Differences between normal diet group (ND), high fat diet group (HFD), adzuki bean extract administration group with high fat diet (HFD V50, HFD V200) and adzuki bean extract administration group with normal diet (ND V200) were determined by two-way ANOVA It became. The resulting values are expressed as mean ± standard error of the mean (SEM). A p value of <0.05 was determined to be statistically significant.

Example 1. Results of ultra-high-performance liquid chromatography (UPLC) analysis of red beans according to the extraction method of red beans YV1-138 or its relatives

Analysis was performed using ultra-high-performance liquid chromatography (UPLC) to identify changes in the compound composition according to the extraction method of the extract of adzuki bean YV1-138 or its related species. Dionex Ultimate 3000 was used for UPLC, ACQUITY UPLC BEH C18 1.7 μm was used for column, UV 205 nm, 260 nm, flow rate 0.4 ml/min for detecoter, solvent A was water with 0.1% TFA, and solvent B was ACN ( acetonitrile) with 0.1% TFA was used.

As a result of analysis using UV 205nm, it was confirmed that the primary extract (A) using 80% ethanol contained esters and peptide compounds, while the 80% ethanol extract was freeze-dried and separated and purified again with 2-propanol (B ), esters and peptide compounds were not identified, so it was confirmed that esters and peptide compounds were removed.

As a result of analysis using UV 260nm wavelength under the same conditions, there was only a small amount of effective polyphenolic compounds in the 80% ethanol extract, but it was confirmed that the polyphenolic compound ratio increased when separated and purified with 2-propanol. It can be seen that phenolic compounds exhibit antidiabetic activity (FIG. 1).

Example 2. Evaluation of alpha-glucosidase (anti-diabetic) inhibitory activity of red beans according to extraction method and extraction concentration

Example 2-1. Evaluation of alpha-glucosidase inhibitory activity of red beans according to extraction method

The alpha-glucosidase inhibitory activity of red bean YV1-138 and the root system prepared by the extraction method prepared in Experimental Example 2 was evaluated by the method of Experimental Example 3.

As a result of analysis of alpha-glucosidase inhibitory activity according to secondary extraction using 80% ethanol primary extract of red bean YV1-138, in the case of 80% ethanol primary extract, IC ₅₀ was 6.4ug/ml based on 22-fold activity was shown to be excellent. The secondary extract using 25% ethanol had an IC ₅₀ value of 8.2ug, which decreased the activity, whereas the secondary extract using 50% ethanol had an IC ₅₀ value of 4.3ug, which was about 50% more active than the primary extraction with 80% ethanol. It was confirmed that the degree increased, and in the case of the secondary extraction using 2-propanol, it was confirmed that the activity was increased by 3.4 times compared to the primary extraction with 1.9ug and the activity was excellent by 74 times compared to acarbose (Table 1).

sample 80% ethanol
primary extract 80% ethanol
Primary &
25% ethanol
secondary extract 80% ethanol
Primary &
50% ethanol
secondary extract 80% ethanol
Primary &
2-Propanol
secondary extract Akavoz IC ₅₀ (μg/ml) 6.4 8.2 4.3 1.9 140.5 IC _50: Concentration of extract that inhibits alpha-glucosidase activity by 50%

As shown in Table 1, in the case of secondary extraction using 50% ethanol or 2-propanol, it was confirmed that the alpha-glucosidase inhibitory activity significantly increased.

Example 2-2. Evaluation of alpha-glucosidase inhibitory activity of red beans according to extraction method and extract concentration

In comparison of the inhibitory activity according to the concentration of the extract, the primary extract using 80% ethanol inhibited about 19.5% at 3.3ug/ml. The 25% ethanol secondary extract suppressed about 18.4% at 3.3ug/ml, while the 50% ethanol secondary extract inhibited 41.8% at 3.3ug/ml, and the secondary extract using 2-propanol inhibited 3.3ug/ml By inhibiting 88.4%, it was confirmed that alpha-glucosidase inhibitory activity was the most excellent (Table 2).

sample Inhibition rate according to extract concentration IC ₅₀ (μg/ml) Concentration (μg/ml) Inhibition rate (%) 80% ethanol
primary extract 13.3 91.7 ± 0.48 6.4 6.7 65.7±2.03 3.3 19.5 ± 1.2 80% ethanol
Primary &
25% ethanol secondary extract 13.3 84.4 ± 0.51 8.2 6.7 38.7 ± 1.51 3.3 18.4 ± 0.73 80% ethanol
Primary &
50% ethanol secondary extract 6.7 80.7 ± 0.51 4.3 3.3 41.8 ± 2.17 1.7 8.6 ± 1.17 80% ethanol
Primary &
2-propanol secondary extract 3.3 88.4 ± 1.15 1.9 1.7 44.72 ± 0.42 0.8 18.5 ± 1.87 Akavoz 333 71.2 ± 4.4 140.5 166 57.0 ± 3.5 83 71.2 ± 2.9 Alpha-glucosidase inhibitory activity (%) = (A _untreated -A _sample ) / A _untreated × 100

As shown in Table 2, even when comparing the alpha-glucosidase inhibition rate according to the concentration of the extract, in the case of secondary extraction using 50% ethanol or 2-propanol, the alpha-glucosidase inhibitory activity The bar increased about 2 to 5 times, it was confirmed that the antidiabetic effect significantly increased.

Example 2-3. Evaluation of thermal stability and alpha-glucosidase inhibitory activity of red beans according to extraction methods

After concentrating the 2-propanol extract at 80° C., the results of measuring the antidiabetic activity were similar to those in which heat was not applied. That is, since the results obtained when heat was applied and when heat was not applied were similar, it was confirmed that the extract had thermal stability (Table 3).

sample 80% ethanol
extract (primary extract) 2-sopropanol
extract (secondary extract) unheated Heating (80℃) unheated Heating (80℃) IC ₅₀ (μg/ml) 6.4 366 1.9 2.1

As shown in Table 3, when heated at 80 ° C., when first extracted with 80% ethanol, when second extracted with 2-sopropanol, thermal stability was excellent, and alpha-glucosidase inhibitory activity was confirmed to increase. did

Example 3. Evaluation of alpha-glucosidase inhibitory activity of red beans according to 2-propanol solvent treatment conditions

When 2-propanol was directly used as the primary extraction solvent instead of 80% ethanol, the antidiabetic activity of the extract was assayed. After adding 20 L of 2-propanol per 1 kg of sample to the pulverized red bean sample and extracting for 48 hours, the alpha-glucosidase inhibitory activity was measured and it was confirmed that the antidiabetic activity was not shown.

After first extracting red bean YV1-138 with 80% ethanol, removing the ethanol with a vacuum concentrator, immediately adding 20 ml of 2-propanol per 1 g of sample without going through freeze-drying in the extract state, followed by stirring and extraction for 24 hours. proceeded. After 24 hours, the supernatant was separated by centrifugation at 3,000 rpm, and after removing 2-propanol from the solution again using a vacuum concentrator, a sample was prepared by freeze-drying.

As a result of testing the alpha-glucosidase inhibitory activity on the 2-propanol extract that was not subjected to the lyophilization extraction process after the first extraction, the IC ₅₀ was 2.3 μg/ml, and the 2-propanol extract after freeze-drying (IC ₅₀ 1.9 μg /ml) and antidiabetic activity were similar.

In addition, in comparison of the extraction yield, the yield of the extract treated with 2-propanol in the sample freeze-dried after the primary extraction using 80% ethanol was 1.5%, whereas the freeze-drying process was omitted and the concentrate was directly treated with 2-propanol. It was confirmed that the yield of the extracted extract was better at 2.7% (Table 4).

sample 80% Ethanol Primary &
2-propanol without lyophilization extraction 80% Ethanol Primary &
Lyophilized 2-propanol extract IC ₅₀ (μg/ml) 2.3 1.9

Example 4. Evaluation of fasting blood glucose changes in animal experimental models

The improvement effects of red bean extract (V) on body weight and hyperglycemia were confirmed in obese and diabetic mice fed a high-fat diet.

Obese and insulin-resistant diabetic mice were prepared by administering a 45% kcal high-fat diet to male mice, and 50 or 200 mg/kg red bean extract (V) was mixed with the high-fat diet and fed for 8 weeks.

Compared to the normal group, it was confirmed that body weight increased when the high-fat diet was consumed, and on the other hand, it was confirmed that there was an effect of weight improvement in the group consuming the feed mixed with the red bean extract in the high-fat feed (FIG. 2). In addition, unlike the normal group, it was confirmed that blood sugar was significantly reduced in the group consuming the feed in which the adzuki bean extract was mixed with the high-fat feed (FIG. 3).

Through this, it was confirmed that the extract of red beans has an effect of alleviating hyperglycemia caused by weight improvement and diabetes.

From the above description, those skilled in the art to which the present invention belongs will be able to understand that the present invention can be implemented in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the claims to be described later and equivalent concepts rather than the detailed description above are included in the scope of the present invention.

National Academy of Agricultural Sciences KACC98056P 20181030

Claims (10)

A food composition for preventing or improving diabetes or obesity, comprising a secondary extract of adzuki bean variety YV1-138 or a related species thereof.
The food composition according to claim 1, wherein the extract is obtained by primary extraction with 15 to 95% ethanol and secondary extraction with an organic solvent.
The method of claim 2, wherein the organic solvent of the secondary extraction is petroleum ethanol, 2-propanol, ether, cyclohexane, benzene, chloroform, ether, ethyl acetate, acetone, isopropyl alcohol, methylene chloride, xylene, glycerin, Ethyl acetate, carbon sulfide, butanol, and at least one selected from methanol, a food composition.
The food composition according to claim 2, wherein the organic solvent of the secondary extraction is 15 to 95% ethanol or 2-propanol.
The food composition according to claim 1, wherein the extract increases alpha-glucosidase inhibitory activity.
The food composition according to claim 1, wherein the extract increases alpha-glucosidase inhibitory activity by 2 to 5 times compared to 15 to 95% ethanol primary extraction.
The food composition according to claim 1, wherein the extract increases heat stability compared to 15 to 95% ethanol primary extraction.
The food composition according to claim 1, wherein the extract has an anti-obesity activity.
The food composition according to claim 1, wherein the red bean variety YV1-138 is deposited under accession number KACC98056P.
A pharmaceutical composition for preventing or treating diabetes or obesity, comprising a secondary extract of adzuki bean variety YV1-138 or a related species thereof.

Images